Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

Dan Atkins, vice president of digital innovation and insight at Shionogi Europe ... for COVID-19 and respiratory syncytial virus (RSV). Join the conversation, on Tuesday 28th January @ 10 am ...

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental A trio of respiratory illnesses — flu, COVID-19 and RSV — is sweeping the U.S. and leaving a trail of coughing and aching ...